Curanex highlights patient case study in treatment of cancer cachexia

Curanex (CURX) highlighted a patient case study that management believes further supports the company’s strategic interest in treatment of cancer cachexia. The company said, “The case involved “Johnny,” a senior dosimetrist at a premier cancer hospital in the Northeast, who was under the care of physicians at Memorial Sloan Kettering Cancer Center for a pancreatic neuroendocrine tumor. According to records authorized by the patient for Company use, Johnny had previously undergone surgery for kidney cancer and later underwent MR Cholangiogram follow-up imaging at MSK in connection with that diagnosis. During the course of his disease, he experienced substantial physical decline, including poor overall condition, abdominal pain, abdominal distension, worsening pain after meals, frequent urination and other symptoms associated with serious disease burden. Following use of Phyto-N, the patient reported meaningful symptomatic improvement within approximately one month, including increased energy, normalization of complexion, resolution of urinary frequency and disappearance of abdominal pain. Follow-up laboratory testing approximately three months later showed substantial improvement in previously elevated pancreatic biomarkers and related measures. Serum amylase improved from 191 to 90, returning to the normal range of 28 to 100. Serum lipase improved from 298 to 52, returning to the normal range of 13 to 60. Triglycerides improved from 164 to 77, while HDL and LDL levels returned to normal ranges. Follow-up MRI later indicated stable disease, including unchanged main ductal dilatation up to 0.6 cm and an unchanged 0.8 cm hypervascular mass. According to the case report, the patient was able to continue normal daily activities and work for more than two years before ultimately undergoing surgical resection at MSK. Management believes the broader significance of this case may extend beyond the individual tumor setting because one of the most devastating consequences of advanced cancer is cachexia, a multifactorial wasting syndrome that can sharply reduce strength, physical function, quality of life and the ability to remain on treatment. The National Cancer Institute describes cancer cachexia as a wasting syndrome involving weakness, fatigue, and loss of skeletal muscle and fat, and estimates it can occur in up to 80% of people with advanced cancer, depending on tumor type and treatment response. Cancer cachexia is especially common in advanced pancreatic cancer.”